Last month, Johnson & Johnson (J&J) announced that its Phase 1/2a in-human clinical trial of its potential COVID-19 vaccine was expected to begin in July – instead of September as initially scheduled. On Thursday, as reported by Fierce Pharma, J&J chief scientific officer Paul Stoffels confirmed the accelerated timeline, saying that the company has seen […]